A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Evaluate the safety of TORL-5-700 as a monotherapy
Timeframe: though study completion, an average of 2.5 years
Assess the antitumor activity of TORL-5-700 as monotherapy
Timeframe: though study completion, an average of 2.5 years
Evaluate the safety of TORL-5-700 in combination with other agents
Timeframe: though study completion, an average of 2.5 years
Determine the Maximum Tolerated Dose (MTD)
Timeframe: 21 days from the start of treatment
Determine the Recommended Phase 2 Dose (RP2D)
Timeframe: 21 days from the start of treatment